Pfizer's Elelyso nabs Australian approval; Judge allows jawbone-risk claims against Novartis;

@FiercePharma: Top story in FiercePharmaMarketing Weds: Who gets the likes when it comes to job hunting? Think J&J, Novartis and Biogen Idec. Article | Follow @FiercePharma

@TracyStaton: Here's an idea for AZ's full-of-promises execs: Tie pay to opportunity cost. More | Follow @TracyStaton

@EricPFierce: German Merck invests €50M in biologics capacity at Italy plant. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: CIA abandons use of vaccine programs for spying. Story from FierceVaccines | Follow @CarlyHFierce

> Elelyso, an enzyme replacement therapy for Gaucher disease developed by Pfizer ($PFE) and Protalix BioTherapeutics ($PLX), won regulatory approval in Japan. Release

> A Minnesota judge decided not to toss out failure-to-warn claims against Novartis ($NVS), related to its cancer drug Aredia and allegations that it can cause osteonecrosis of the jaw. Report

> Purdue Pharma recruited Saeed Motahari to be its senior vice president and chief commercial officer; Motahari had been a VP of U.S. sales and marketing for AbbVie's ($ABBV) specialty brands business. Release

> The drug distributor Celesio, recently purchased by McKesson Corp. ($MCK), rejigged its management team, with CFO Marion Helmes resigning to be replaced by McKesson's Alain Vachon. Report

> Acura Pharmaceuticals ($ACUR) settled a patent fight with Novartis' generics unit Sandoz, allowing the generics maker to roll out its version of the oxycodone drug Aversion under license from Acura. Report

Medical Device News

@FierceMedDev: Neovasc reports higher 1Q revenues, lower expenses and losses. Story | Follow @FierceMedDev

@VarunSaxena2: St. Jude Medical sticking with renal denervation, releases EnligHTN study data at EuroPCR2014. Release | Follow @VarunSaxena2

@MichaelGFierce: Smallest, fastest nanomotor moves drugs and releases them on demand. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Wound-care outfit Healogics is up for grabs with $1B pricetag. Article | Follow @EmilyWFierce

> Cianna picks up $10M to expand its cancer-fighting device. Item

> Wound-care outfit Healogics is up for grabs with $1B pricetag. Report

> Zimmer CEO insists that no salespeople will be cut after Biomet merger. Story

Biotech News

@FierceBiotech: Editors @JohnCFierce, @DamianFierce and @EricPFierce will chat w/ experts and break down #ASCO2014. More to follow. Sponsored by @Covance. | Follow @FierceBiotech

@JohnCFierce: The R&D rankings: Big biotech once again makes Big Pharma look small. Report | Follow @JohnCFierce

@DamianFierce: So, who's going to run $CELG when Bob Hugin hangs it up? More | Follow @DamianFierce

@EmilyMFierce: ICYMI, this week's edition of FierceBiotech Research features lots of ASM2014 news. Report | Follow @EmilyMFierce

> Sarepta bets on DMD drug approval with a $25M plant buy. Article

> Third Rock builds a new West Coast biotech with an eye on cancer drugs. Story

Pharma Manufacturing News

> Global sweep nabs 237 counterfeiting suspects. News

> Moderna names big names to manufacturing advisory board. Item

> Logistics company RXTPL rails at FDA for identifying it in drug seizure report. Article

> Teva recalls drugs made by India's Emcure over lab testing issues. Story

> India to double its drug inspection staff. Report

Vaccines News

> Pandemic flu vaccine research poses risk of unintended release. Story

> Glaxo announces 5-year price freeze for post-GAVI countries. Article

> CIA abandons use of vaccine programs for spying. More

> Sanofi C. diff vaccine shows immune response in PhII trial. Report

> Kymab, Gates Foundation to team up for malaria, HIV antigen discovery. Item

And Finally... Who needs obesity drugs when a grueling, painful diet-and-exercise program works? Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…